Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a treatment for metabolic ...

Grail is preparing to file for FDA approval of its Galleri test for detecting multiple cancers from a single blood test after ...

The new PATHFINDER 2 trial data comes from almost 26,000 people out of a total study cohort of around 36,000, all aged over ...

The FDA has launched a review of clinical trials that plan to send American citizens' living cells to 'hostile' countries – ...

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...

It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ...

After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more ...

BIO 2025 this year came at a uniquely fraught moment for vaccination in the United States just days after HHS Secretary ...

Just a year ago, the GenAI buzz in pharma felt like the start of a gold rush. Leaders greenlit pilots. Teams spun up proof-of ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

From the practical wisdom of emphasising exercise to improve survival in colon cancer to the association of glucagon-like ...

Originally employed in atomic physics, mass spectrometry is now an indispensable tool in modern science, and importantly ...